bms561392 and Inflammatory-Bowel-Diseases

bms561392 has been researched along with Inflammatory-Bowel-Diseases* in 1 studies

Reviews

1 review(s) available for bms561392 and Inflammatory-Bowel-Diseases

Article	Year
BMS-561392. Bristol-Myers Squibb. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:5 Bristol-Myers Squibb Pharma Co is developing the tumor necrosis factor-alpha (TNF alpha) converting enzyme inhibitor BMS-561392 (DPC-333) for the potential treatment of diseases characterized by overproduction of TNF alpha, such as rheumatoid arthritis (RA). A phase IIa trial in RA patients had commenced by April 2001, and by October 2002, BMS-561392 was also under investigation for the potential treatment of inflammatory bowel disease. Topics: ADAM Proteins; ADAM17 Protein; Animals; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Inflammatory Bowel Diseases; Metalloendopeptidases; Quinolines; Technology, Pharmaceutical; Tumor Necrosis Factor-alpha	2003

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:5

Bristol-Myers Squibb Pharma Co is developing the tumor necrosis factor-alpha (TNF alpha) converting enzyme inhibitor BMS-561392 (DPC-333) for the potential treatment of diseases characterized by overproduction of TNF alpha, such as rheumatoid arthritis (RA). A phase IIa trial in RA patients had commenced by April 2001, and by October 2002, BMS-561392 was also under investigation for the potential treatment of inflammatory bowel disease.

Topics: ADAM Proteins; ADAM17 Protein; Animals; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Inflammatory Bowel Diseases; Metalloendopeptidases; Quinolines; Technology, Pharmaceutical; Tumor Necrosis Factor-alpha

2003